Results 1-20 of 69 for drugs speaker:Pádraig O'Sullivan

Road Safety: Statements (17 Apr 2024)

Pádraig O'Sullivan: ...the Minister for Justice is following up on this but we really need to fill as many of the vacant posts as quickly as possible and get back to the numbers we need. I am also concerned about drink and drug driving. Drug driving is becoming increasingly common, which is very concerning. It is good to see the Garda actively policing this. Let me raise my two fundamental issues. I...

Written Answers — Department of Health: Health Services (21 Mar 2024)

Pádraig O'Sullivan: 303. To ask the Minister for Health the impact on current drug reimbursement waiting times that he expects to see as a result of the recruitment of 36 new staff within the decision-making reimbursement process; and if he will make a statement on the matter. [13410/24]

Ceisteanna ar Sonraíodh Uain Dóibh - Priority Questions: Programme for Government (20 Mar 2024)

Pádraig O'Sullivan: ...if possible. Ultimately, what will be spoken about there is how we are, as I have said consistently for three years in the Dáil, laggards in the European context when it comes to reimbursement of drugs. Given that it is the Taoiseach's last day taking questions, I ask that before he departs he look at the possibility of establishing a task force or some kind of specialist group that...

Rare Diseases: Statements (6 Mar 2024)

Pádraig O'Sullivan: ...rapid access to medicines. It has been noted in various medical journals published across Europe that Ireland is consistently at the tail end in a European context when it comes to the approval of drugs. I hate to focus all my time on drugs, but we are looking at delays here of up to 1,100 days, depending on the drug and on the process that it has gone through. I said to the Minister at...

Ceisteanna - Questions: Cabinet Committees (5 Mar 2024)

Pádraig O'Sullivan: .... We have spoken about it before and I welcome its publication, but the reality is that the report will not meaningfully reduce the times for which people are waiting for the approval of an orphan drug. When this Government took office, there was an average of more than 900 days for a drug to be approved through the HTA process. When this Government finishes office, which will be any...

Written Answers — Department of Health: Medicinal Products (5 Mar 2024)

Pádraig O'Sullivan: 706. To ask the Minister for Health if he will supply data, in tabular form, for the ten fastest, and ten slowest approvals of orphan drugs by the HSE, by year (for the period 2014 to 2023), stating the date on which the applications for said drugs were received by the HSE and the data on which a reimbursement decision was subsequently made; and if he will make a statement on the matter....

Written Answers — Department of Health: Medicinal Products (5 Mar 2024)

Pádraig O'Sullivan: 707. To ask the Minister for Health if he can confirm if the HSE’s systems can extract spending on reimbursements in respect of orphan drugs; and if so, to provide in tabular form, the amount spent in this respect in each year 2014-2023 inclusive; and if he will make a statement on the matter. [10301/24]

Written Answers — Department of Health: Medicinal Products (29 Feb 2024)

Pádraig O'Sullivan: 26. To ask the Minister for Health if he will supply data for the ten fastest and ten slowest approvals of orphan drugs by the HSE, by year, for the period 2014 to 2023, stating the date on which the applications for said drugs were received by the HSE and the date on which a reimbursement decision was subsequently made, in tabular form; and if he will make a statement on the matter. [9461/24]

Written Answers — Department of Health: Medicinal Products (28 Feb 2024)

Pádraig O'Sullivan: 137. To ask the Minister for Health if the HSE’s systems can extract spending on reimbursements in respect of orphan drugs; and if so, the amount spent in this respect in each year 2014-2023 inclusive, in tabular form. [9451/24]

Ceisteanna ar Pholasaí nó ar Reachtaíocht - Questions on Policy or Legislation (14 Feb 2024)

Pádraig O'Sullivan: ...of the Mazars report and in instigating the review of the national rare disease plan. That is a cause for optimism. Nonetheless, as we found out this year, there is no designated funding for new drugs for rare diseases and the plan depends on savings being made elsewhere. I am concerned about how the recommendations of the rare disease plan, when it is published, will be implemented in...

Ceisteanna - Questions: Cabinet Committees (30 Jan 2024)

Pádraig O'Sullivan: I want to raise again the issue of rare diseases. The Taoiseach might have seen the news that last week, thankfully, the drug Libmeldy was approved for patients who suffer from metachromatic leukodystropohy, MLD. I pay tribute to the parent of a child who passed away a number of years ago. Les Martin sadly lost his son, Cathal, a few years ago to this disease. We saw and heard from Les...

Written Answers — Department of Health: Medicinal Products (17 Jan 2024)

Pádraig O'Sullivan: 1513. To ask the Minister for Health if the additional €92 million allocated to health as part of the revised estimates volume will include funding for new drugs in 2024; how much of that funding will be allocated to new drugs; if he will provide further information and clarity on the matter; and if he will make a statement on the matter. [56612/23]

Estimates for Public Services 2023: Programme for Government (5 Dec 2023)

Pádraig O'Sullivan: I raise again the issue of rare diseases. While I welcome much of the progress we have achieved in the past two years in government, particularly with the number of drugs to which people have access - more than 80 at this stage, which is great progress - I still feel somewhat disappointed that next year's budget did not contain a stand-alone budget for new drugs for rare diseases. I know...

An tOrd Gnó (Atógáil) - Order of Business (Resumed) (17 Oct 2023)

Pádraig O'Sullivan: ...in recent weeks. However, I feel this is an issue that warrants raising again. I raised with the Taoiseach earlier this year that there was an underspend for 2022, particularly in the area of new drugs. I received a response to a parliamentary question to the effect that approximately €10 million was drawn down of the €30 million allocated for 2022. I am concerned that...

Ceisteanna ar Pholasaí nó ar Reachtaíocht - Questions on Policy or Legislation (5 Oct 2023)

Pádraig O'Sullivan: I note the Minister for Health is also present. I raise with him an article published in The Irish Timesthis morning about the possible cutting of funding for new drugs in the budget. I do not expect the Minister to reveal the budget here and I know negotiations are still ongoing. However, a number of us have been contacted by stakeholders and patients' groups about their concerns leading...

Ceisteanna - Questions: Cabinet Committees (4 Jul 2023)

Pádraig O'Sullivan: I was here two or three weeks ago and I asked the Taoiseach about an alleged underspend under the Primary Care Reimbursement Service, PCRS, for new drugs. We budgeted €30 million to be spent by the Minister in 2022, but I am being told that only €9.4 million of that has actually been drawn down. As a follow-up to that, I am still awaiting the Taoiseach's response. Yet, there...

Ceisteanna - Questions: Cabinet Committees (14 Jun 2023)

Pádraig O'Sullivan: ...about the previous drawdown from the primary care reimbursement scheme, PCRS. To be fair to the Minister for Health, he has provided €100 million over the past three years specifically for new drugs in this space but, unfortunately, €30 million of that was meant to be drawn down in 2022 and, according to the PCRS, only €9.4 million was drawn down. There might be an...

Written Answers — Department of Health: Departmental Data (14 Jun 2023)

Pádraig O'Sullivan: 148. To ask the Minister for Health to outline the expenditure levels of new medicines and new uses of existing medicines in 2022 on an in-year basis under the oncology drug management system; and if he will make a statement on the matter. [28652/23]

Written Answers — Department of Health: Health Service Executive (13 Jun 2023)

Pádraig O'Sullivan: ...current members of the implementation working group set up to consider and progress the various recommendations contained in a report (details supplied) into governance arrangement to support HSE drug reimbursement; the dates of each of the meetings of the working group; the target month for the working group to report to Government; the consultation process; and the work that has been...

Ceisteanna Eile - Other Questions: Health Services Staff (1 Jun 2023)

Pádraig O'Sullivan: .... There are various steps being taken on the positive front on foot of that, including increasing transparency through an online portal that will keep people informed about the progress of the drug in question in terms of reimbursement. The problems still prevail in respect of waiting times for reimbursement, however. I also welcome the fact that the Minister has commenced a review of...